Neoadjuvant chemotherapy can improve oncologic outcomes and overall survival rate. However, not all patients respond well during treatment, and continuous treatment will be painful, costly, and even increase risk of progression. Thus, early stratification of treatment response and screening of patients who may not be effective in treatment is very important. We investigated the value of T1 and T2 mapping MRI in response evaluation and found that T2 value showed a significant difference between groups of pre and 1-week post-treatment, while the T1 value had no statistical difference. T2 mapping may be a useful functional biomarker for early responses evaluation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords